Eisai Missionad Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wednesday, March 10 Lecture Time: 12:45 - 13:00 Live Discussion: 17:00 - 17:30 Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE, Phase 3 Studies of Aducanumab in Patients with Early Alzheimer's Disease Session: Aβ Targeting Therapies in AD 2 Saturday, March 13 Lecture Time: 12:45 - 13:00 Live Discussion: 17:30 - 18:00 Evaluation of Aducanumab Efficacy in Early Alzheimer's Disease. Session: Aβ Targeting Therapies in AD 2 Saturday, March 13 Lecture Time: 13:00 - 13:15 Live Discussion: 17:30 - 18:00  Evaluation of Aducanumab Safety in Early Alzheimer's Diseas...

Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data - Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms - Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation - Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer's Disease News provided by Share this article Share this article WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ -- Eisa...